William J. Burman, MD

• Professor of Medicine
• University of Colorado School of Medicine
• Medical Director, Infectious Diseases Clinic
• Denver Public Health
• Denver, CO

 

Research Topics

• Diagnosis and management of HIV-related tuberculosis
• New drug development for tuberculosis treatment
• Strategies for use of antiretroviral therapy
• Adherence to medical therapy

 

Lecture and Writing Topics

• Diagnosis and management of HIV-related tuberculosis
• New drug development for tuberculosis treatment
• Adherence to HIV care and treatment

 

Current Professional Summary

Dr Burman is the Medical Director of the Infectious Diseases Clinic of Denver Public Health, a clinic that provides comprehensive care for for approximately 1200 persons with HIV infection. He has been the Chair of the Science Planning Committee of the Tuberculosis Trials Consortium (TBTC) since 1997 and protocol chair of 3 TBTC studies. Dr Burman is a member of the Tuberculosis Working Group of the AIDS Clinical Trials Group (ACTG) and a protocol team member of 3 ACTG studies related to tuberculosis. He is a protocol team member of the Strategic Timing of Antiretroviral Therapy (START) study, a large international trial of timing of the initiation of antiretroviral therapy.

 

Committees and Organizations

• Chair, Tuberculosis section of the Public Health Service guidelines for prophylaxis and management of opportunistic infections (2010)
• Chair, CDC working group to update guidelines for managing drug interactions between rifamycins and antiretroviral drugs (1998-present)
• Member, Training Working Group of MTCT-Plus and ICAP (program for comprehensive HIV care in high-burden countries); trainer for South Africa, Kenya, Uganda, Rwanda, and Ethiopia (2003-2008)
• Member, Research Committee of the Infectious Diseases Society of America (2006-2010)
• Member, Advisory Council for the Elimination of Tuberculosis, Department of Health and Human Services (2005-2009)

 

Honors and Awards

• Outstanding teaching, Infectious Diseases Division, University of Colorado Health Sciences Center (2001-2002)
• Outstanding teaching, Infectious Diseases Division, University of Colorado Health Sciences Center (1997-1998)
• Joseph H. Bates Young Investigator Award, American Thoracic Society (1997)
• Outstanding scholarly achievement, Denver Health and Hospital (1997)

 

Education

• Whitman College, BA in Biology and Chemistry (1981)
• Mayo Medical School, MD (1985)
• Fitzsimons Army Medical Center, Internship and Residency in Internal Medicine (1988)
• Fitzsimons Army Medical Center, Chief Medical Resident (1989)
• University of Colorado School of Medicine, Infectious Diseases Fellowship (1995)

 

Selected Publications

1. Infectious Diseases Society of America. Grinding to a halt: the effects of the increasing regulatory burden on research and quality improvement efforts. Clin Infect Dis. 2009;49:328-335.
2. Burman W, Grund B, Neuhaus J, et al. Episodic antiretroviral therapy increases HIV transmission risk compared with continuous therapy: results of a randomized controlled trial. JAIDS. 2008;49:142-150.
3. Burman W, Benator D, Vernon A, et al. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med. 2006;173:350-356.
4. Burman WJ, Goldberg S, Johnson JL, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med. 2006;174:331-338.
5. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-2296.
6. Gardner EM, Burman WJ, Maravi ME, Davidson AJ. Selective drug taking during combination antiretroviral therapy in an unselected clinic population. JAIDS. 2005;40:294-300.
7. El-Sadr WM, Burman WJ, Grant LB, et al. Discontinuation of prophylaxis for Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med. 2000;342:1085-1092.
8. Lundberg BE, Davidson AJ, Burman WJ. Epidemiology of Pneumocystis carinii pneumonia in an era of effective prophylaxis: the relative contribution of non-adherence and drug failure. AIDS. 2000;14:2559-2566.
9. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet. 1999;353:1843-1847.